Loading
Life sciences · Journal article
Acs Materials Letters · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Radiotherapy plays an indispensable role in clinical cancer treatment. Designing dual-modal agents for computed tomography (CT) imaging and radiotherapy sensitization remains a great challenge in tumor therapy. In this study, we designed and synthesized bismuth-based nanomaterials (Bi2Se3-TPP, TPP refers to triphenylphosphonium) with mitochondria-preferential accumulation and favorable CT imaging performance and prominent glutathione peroxidase (GPx)-like catalytic activity. The obtained Bi2Se3-TPP can efficiently catalyze the reaction between H2O2 and glutathione (GSH), which induces intracellular GSH depletion and disrupts cellular antioxidant defense. Compared to Bi2Se3-PEG, Bi2Se3-TPP exhibited superior radiosensitization efficiency due to its mitochondrial targeting capability and impaired cellular reactive oxygen species (ROS)-scavenging ability, which facilitates ROS accumulation upon irradiation enhanced ROS generation capacity. In vivo studies demonstrated that Bi2Se3-TPP possessed good biocompatibility, achieving a tumor suppression rate of up to 82.6% in the synergistic treatment group, indicating significant potential for tumor diagnosis and therapy.